About
Novartis is an innovative medicines company.Every day,we work to reimagine medicine to improve and extend people’s live s so that patients,healthcare professionals and societies are empowed in the face of serious disease.Our medicines reach more than250million people worldwide。
Patients and caregivers
Information for patients and their caregivers including clinical trial recruiting,managed access programs,funding opportunities for patient organizations and side effects reporting。
Healthcare professionals
资源for physicians and other healthcare professionals including clinical trial recruiting,grant funding,congresses and country-level information。
Research&development
Discover how Novartis turns breakthrough science into transformative,high-value treatments。
环境,自然和governance
Learn about our commitments to making a positive impact on the world by providing access to innovative medicines,protecting the environment,and upholding high ethical standards.Explore the Novartis in Society Integrated Report。
Investors
Updates and resources for investors including financial information,disclosures,events,share price,ESG and reporting。
新闻,新闻
Information for journalists including media releases,statements,stories,multimedia resources and more。
Careers
Novartis is hiring!Find open positions,learn more about our strategy and culture,and apply today。
主页
Working together,we can reimagine medicine to improve and extend people’s lives。
日期,日期:Tuesday,March052024,10:00CETPlace:St.Jakobshalle,Basel,Switzerland
Invitation to the Annual General Meeting(PDF0.4MB)
Brochure“Compensation Votes at the 2024 Annual General Meeting”(PDF0.1MB)
PDF0.7MB的“Registration/appointment of proxy”for registered shareholders
介质继电器,介质继电器
Voting results(PDF0.1MB)
最小(PDF0.2MB-German)
Read the Annual Report2023 or the“Novartis in Society Integrated Report2023”
Datum:Dienstag,05。ärz20241.00MEZ开始,开始:St.Jakobshalle,Basel,Schweiz
EDF0.4MB
Broschüre“Abstimmmungenüber die Vergütungen an der ordentlichen Generalversammlung 2024”(PDF0.1MB)
usterformular“Anmeldung/Vollmachtserteilung”für registrierte Aktionäre(PDF0.7MB)
介质,介质
PDF0.1MB
Protokoll(PDF0.2MB)
Lesen Sie den Geschäftsbericht2023(in Englisch)oder den“Novartis in Society IntegrierGeschäftsbericht2023”(in Deutsch und Englisch)
AgendaEnglish(PDF0.3MB) Deutsch(PDF0.3MB)
Shareholder Information Brochure“Proposed Spin-off of Sandoz”English(PDF0.3MB) Deutsch(PDF0.3MB)
Sandoz Group AG and other related documents
介质继电器,介质继电器 English(PDF0.2MB) Deutsch(PDF0.2MB) FranCaais(PDF0.2MB)
Voting resultsEnglish(PDF0.1MB) Deutsch(PDF0.1MB)
最小,最小Deutsch(PDF0.2MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF0.4MB) Deutsch(PDF0.4MB) FranCaais(PDF0.4MB)
Brochure“Explanations of the Board of Directors on the Amendment of the Articles of Incorporation”English(PDF0.1MB) Deutsch(PDF0.2MB) FranCaais(PDF0.1MB)
Statement regarding Agenda Item6.1–Participation at General Meetings by Electronic Means(Article 12a of the Articles of Incorporation)English(PDF0.5MB) Deutsch(PDF0.5MB) FranCaais(PDF0.5MB)
Brochure“Compensation Votes at the 2023 Annual General Meeting”English(PDF0.1MB) Deutsch(PDF0.1MB) FranCaais(PDF0.1MB)
Background information on John D。Young(updated)(PDF0.1MB)
Voting resultsEnglish(PDF0.1MB) Deutsch(PDF0.1MB) FranCaais(PDF0.1MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF0.3MB) Deutsch(PDF0.3MB) FranCaais(PDF0.3MB)
介质继电器,介质继电器 English(PDF0.3MB) Deutsch(PDF0.3MB) FranCaais(PDF0.3MB)
Voting resultsEnglish(PDF0.2MB) Deutsch(PDF0.2MB) FranCaais(PDF0.2MB)
最小,最小Deutsch(PDF0.1MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF4.2MB) Deutsch(PDF4.2MB) FranCaais(PDF4.2MB)
Brochure“Proposed Spin-Of of Alcon”English(PDF0.9MB) Deutsch(PDF0.9MB) FranCaais(PDF0.9MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF0.3MB) Deutsch(PDF0.3MB) FranCaais(PDF0.1MB)
Letter from the Chairman of the Compensation Committee Concerning the 2017 Compensation Report(PDF0.1MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF0.8MB) Deutsch(PDF0.8MB) FranCaais(PDF0.9MB)
Novartis response to the report issued by proxy advisor ISS on February072017(PDF0.2MB)
Voting resultsEnglish/Deutsch/Fran^ais(PDF0.6MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF0.7MB) Deutsch(PDF0.8MB) FranCaais(PDF0.8MB)
Comment:Further Share Repurchase Program,item5 of the Agenda(PDF0.1MB)
Voting resultsEnglish/Deutsch/Fran余额ais(PDF1.0MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF3.6MB) Deutsch(PDF3.6MB) FranCaais(PDF3.7MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF1.2MB) Deutsch(PDF1.0MB) FranCaais(PDF1.0MB)
介质继电器,介质继电器 English(PDF0.2MB) Deutsch(PDF0.2MB) FranCaais(PDF0.3MB)
Voting resultsEnglish/Deutsch/Fran^ais(PDF1.2MB)
Agenda and Shareholder Information on the Compensation VotesEnglish(PDF0.5MB) Deutsch(PDF0.4MB) FranCaais(PDF0.9MB)
Voting resultsEnglish/Deutsch/Fran^ais(PDF0.5MB)